mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Live updates

1. 1h ago

   Moderna's mRNA cancer vaccine succeeds in Phase 3 melanoma trial

   Moderna and Merck's personalized mRNA cancer vaccine, paired with pembrolizumab, significantly reduced the risk of melanoma recurrence in a Phase 3 trial. The treatment is tailored to individual tumor mutations, marking a shift from one-size-fits-all approaches. The vaccine helped melanoma patients stay cancer-free longer. This success paves the way for potential FDA approval and a new approach to skin cancer treatment.

   Why it matters

   Melanoma is a serious form of skin cancer with high recurrence rates. Current treatments often have varying degrees of success. The partnership between Moderna and Merck combines cutting-edge mRNA technology with immunotherapy, offering hope for more effective and personalized treatments. The positive Phase 3 trial results are a crucial step toward bringing this innovative treatment to market.

   What is confirmed

   • The personalized mRNA vaccine, paired with pembrolizumab, reduced the risk of melanoma recurrence in a Phase 3 trial.
   • The treatment combines a neoantigen mRNA vaccine with the immunotherapy drug pembrolizumab.
   • The successful trial represents the final clinical step required before seeking FDA approval.

   What to watch next

   • FDA approval process for the mRNA cancer vaccine
   • Potential market launch and availability of the treatment
   • Further research on the vaccine's effectiveness in other types of cancer
   Sources used for this update (5)

   1. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
   2. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
   3. www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
   4. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
   5. www.wbur.org — What does Moderna's melanoma treatment mean for cancer research? We asked 2 local experts
   confidence 100%
2. 4d ago

   Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence in Phase 3 Trial

   Moderna and Merck announced that their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning during a phase 3 clinical trial. The treatment combines a neoantigen mRNA vaccine with the immunotherapy drug pembrolizumab. This successful trial represents the final clinical step required before the companies can seek FDA approval. The results suggest a shift toward treatments tailored to the specific mutations of individual tumors rather than a one-size-fits-all approach to skin cancer.

   Why it matters

   Melanoma is a highly aggressive skin cancer prone to relapse. This trial tests whether mRNA technology, used previously for infectious diseases, can train the immune system to recognize and attack tumor-specific proteins.

   What is confirmed

   • Moderna and Merck developed a personalized mRNA cancer vaccine that reduces melanoma recurrence.
   • The treatment combines an mRNA vaccine with the immunotherapy drug pembrolizumab.
   • The vaccine successfully completed phase 3 clinical trials.

   What to watch next

   • FDA approval decision for the mRNA vaccine
   • Data on long-term survival rates for trial participants
   Sources used for this update (4)

   1. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
   2. www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
   3. www.medicalnewstoday.com — Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
   4. moneymorning.com — Moderna's Cancer Vaccine Just Cleared a Real Phase 3 Bar
   confidence 100%
3. 5d ago

   Moderna and Merck's mRNA Cancer Vaccine Succeeds in Phase 3 Melanoma Trial

   Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage trial, preventing melanoma from returning. The vaccine, which uses Moderna's mRNA technology, achieved its primary goal in the Phase 3 trial. This development has significant implications for the treatment of melanoma and the use of mRNA technology in cancer therapy.

   Why it matters

   Melanoma is a serious form of skin cancer that can be fatal if not treated promptly. Current treatments for melanoma include surgery, chemotherapy, and immunotherapy. The success of Moderna and Merck's mRNA cancer vaccine in a Phase 3 trial marks a significant advancement in the field of cancer therapy. mRNA technology has shown promise in the development of vaccines and treatments for various diseases, including cancer.

   What is confirmed

   • Moderna's stock surged 90% following the announcement of the positive Phase 3 trial results.
   • The mRNA cancer vaccine showed promise in preventing melanoma from returning in patients.
   • Moderna and Merck collaborated on the development of the mRNA cancer vaccine.

   What to watch next

   • Future regulatory approvals and commercialization of the mRNA cancer vaccine
   • Additional trial results and long-term efficacy data
   • Potential applications of mRNA technology in other cancer treatments
   Sources used for this update (5)

   1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
   2. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
   3. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
   4. Ars Technica — mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
   5. Yahoo Finance — Moderna stock surges as melanoma vaccine trial shows "landmark moment"
   confidence 92%